Idexx Laboratories Inc /DE splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Product at $722.9 million, 60% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4,662
|
1,214
|
1,217
|
1,141
|
1,091
|
1,105
|
1,109
|
998
|
954
|
| Product |
2,760
+12.8%
share 59.2%
|
723
+10.2%
share 59.5%
|
719
+9.3%
share 59.1%
|
666
+16.2%
share 58.4%
|
652
+16.5%
share 59.8%
|
656
share 59.4%
|
658
share 59.3%
|
573
share 57.4%
|
560
share 58.7%
|
| Services |
1,902
+10.5%
share 40.8%
|
491
+9.4%
share 40.5%
|
498
+10.2%
share 40.9%
|
475
+11.6%
share 41.6%
|
438
+11.1%
share 40.2%
|
449
share 40.6%
|
452
share 40.7%
|
425
share 42.6%
|
394
share 41.3%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IDXX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westbrook, ME
- SEC filer status
- Large accelerated filer
- SEC CIK
- 874716
Other In Vitro & In Vivo Diagnostic Substances companies
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.